Kyntra Bio, Inc.
KYNBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 2, 2023 | Stifel Nicolaus | Annabel Samimy | $28.00(+62%) | $17.32 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 7, 2025 |
| B of A Securities | downgrade | Neutral →Underperform | Aug 7, 2023 |
| Goldman Sachs | maintain | Sell | Jun 26, 2023 |
| Raymond James | downgrade | Outperform →Market Perform | Jun 25, 2023 |
| B of A Securities | downgrade | Buy →Neutral | Jun 25, 2023 |
| Stifel | downgrade | Buy →Hold | Jun 25, 2023 |
| William Blair | downgrade | Outperform →Market Perform | Jun 25, 2023 |
| Stifel | upgrade | Hold →Buy | Jun 1, 2023 |
| Cowen & Co. | maintain | Market Perform | Feb 27, 2023 |
| Goldman Sachs | maintain | Sell | Feb 22, 2023 |
| Goldman Sachs | maintain | Sell | Feb 20, 2023 |
| William Blair | upgrade | Market Perform →Outperform | Jan 30, 2023 |
| Raymond James | upgrade | Market Perform →Outperform | Jan 25, 2023 |
| B of A Securities | upgrade | Neutral →Buy | Jan 4, 2023 |
| Goldman Sachs | maintain | Sell | Nov 7, 2022 |
| Goldman Sachs | maintain | Sell | May 23, 2022 |
| Goldman Sachs | maintain | Sell | Feb 28, 2022 |
| Goldman Sachs | downgrade | Neutral →Sell | Sep 21, 2021 |
| Raymond James | upgrade | Underperform →Market Perform | Aug 19, 2021 |
| SVB Leerink | maintain | Outperform | Aug 9, 2021 |
| B of A Securities | downgrade | Buy →Neutral | Jul 15, 2021 |
| Stifel | downgrade | Buy →Hold | Jul 15, 2021 |
| JP Morgan | upgrade | Underweight →Neutral | Apr 6, 2021 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $2.96 | $-3.18 | -$1.5M | $2.1M |
| May 11, 2026 | $-3.74 | $-3.36 | $3.7M | $1.6M |
| Mar 16, 2026 | $-3.51 | $-3.89 | $1.3M | $1.7M |
| Nov 10, 2025 | $-1.61 | $-4.01 | $1.1M | $2.4M |
| Aug 11, 2025 | $-3.38 | $-2.25 | $1.3M | $2.6M |
| May 12, 2025 | $0.05 | $0.75 | $2.7M | $1.6M |
| Mar 17, 2025 | $-4.50 | $-2.00 | $3.1M | $24.9M |
| Nov 12, 2024 | $-4.25 | $-7.66 | $46.3M | $34.8M |
News
Kyntra Bio (NASDAQ: KYNB - Get Free Report) and Immatics (NASDAQ: IMTX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends. Profitability This table compares Kyntra Bio and Immatics'
SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The Company also announced that Maykin Ho, Ph.D. has stepped down from the Board of Directors effective September 30, 2026 after nearly eight years of service.
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company's management will be attending and presenting at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026, in New York, NY.
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations under the agreement in exchange for an accelerated upfront payment.
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Kyntra Bio (KYNB) came out with a quarterly loss of $4.68 per share versus the Zacks Consensus Estimate of a loss of $3.18. This compares to a loss of $3.38 per share a year ago.
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company's recent developments.